ADIL
Price:
$1.005
Market Cap:
$6.44M
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.[Read more]
Industry
Biotechnology
IPO Date
2018-07-27
Stock Exchange
NASDAQ
Ticker
ADIL
According to Adial Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -291.06%. This represents a change of 331.99% compared to the average of -67.38% of the last 4 quarters.
The mean historical ROE of Adial Pharmaceuticals, Inc. over the last ten years is -194.40%. The current -291.06% ROE has changed 49.73% with respect to the historical average. Over the past ten years (40 quarters), ADIL's ROE was at its highest in in the June 2018 quarter at 138.56%. The ROE was at its lowest in in the March 2023 quarter at -200.78%.
Average
-194.40%
Median
-261.89%
Minimum
-553.72%
Maximum
406.02%
Discovering the peaks and valleys of Adial Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 126.45%
Maximum Annual ROE = 406.02%
Minimum Annual Increase = -329.28%
Minimum Annual ROE = -553.72%
Year | ROE | Change |
---|---|---|
2023 | -171.47% | -55.87% |
2022 | -388.57% | -29.83% |
2021 | -553.72% | 103.23% |
2020 | -272.46% | 126.45% |
2019 | -120.32% | -54.06% |
2018 | -261.89% | -329.28% |
2017 | 114.23% | -71.87% |
2016 | 406.02% | -180.98% |
The current ROE of Adial Pharmaceuticals, Inc. (ADIL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-371.25%
5-year avg
-301.31%
10-year avg
-194.40%
Adial Pharmaceuticals, Inc.’s ROE is greater than TransCode Therapeutics, Inc. (-597.47%), greater than Aditxt, Inc. (-607.01%), less than Reviva Pharmaceuticals Holdings, Inc. (664.92%), greater than Avenue Therapeutics, Inc. (-749.10%), greater than Applied Molecular Transport Inc. (-218.56%), less than Catalyst Biosciences, Inc. (1.20%), greater than Aileron Therapeutics, Inc. (-47.94%), greater than Bio-Path Holdings, Inc. (-2842.40%), greater than Benitec Biopharma Inc. (-90.14%), greater than Hoth Therapeutics, Inc. (-81.79%), greater than Revelation Biosciences, Inc. (-243.91%), greater than NeuroBo Pharmaceuticals, Inc. (-154.04%), greater than Virax Biolabs Group Limited (-115.10%), greater than RenovoRx, Inc. (-403.38%), greater than Axcella Health Inc. (-3582.11%), less than Better Therapeutics, Inc. (129.80%), greater than Pasithea Therapeutics Corp. (-74.63%), greater than Onconova Therapeutics, Inc. (-144.95%), greater than Diffusion Pharmaceuticals Inc. (-55460.19%), greater than Aeterna Zentaris Inc. (-84.15%), greater than Tonix Pharmaceuticals Holding Corp. (-158.27%),
Company | ROE | Market cap |
---|---|---|
-597.47% | $8.89M | |
-607.01% | $4.28M | |
664.92% | $33.39M | |
-749.10% | $3.15M | |
-218.56% | $11.01M | |
1.20% | $19.42M | |
-47.94% | $86.66M | |
-2842.40% | $3.61M | |
-90.14% | $214.00M | |
-81.79% | $6.14M | |
-243.91% | $3.19M | |
-154.04% | $21.47M | |
-115.10% | $8.86M | |
-403.38% | $24.95M | |
-3582.11% | $0 | |
129.80% | $5.45K | |
-74.63% | $3.78M | |
-144.95% | $20.90M | |
-55460.19% | $8.98M | |
-84.15% | $17.51M | |
-158.27% | $19.46M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Adial Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Adial Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Adial Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Adial Pharmaceuticals, Inc. (ADIL)?
What is the highest ROE for Adial Pharmaceuticals, Inc. (ADIL)?
What is the 3-year average ROE for Adial Pharmaceuticals, Inc. (ADIL)?
What is the 5-year average ROE for Adial Pharmaceuticals, Inc. (ADIL)?
How does the current ROE for Adial Pharmaceuticals, Inc. (ADIL) compare to its historical average?